BAP5191 / Bacoba - LARVOL DELTA

Safety, Tolerability, and Pharmacokinetics of BAP5191 in Healthy Adults Following Topical Application of Repeat Doses (clinicaltrials.gov) - P1 | N=24 | Completed | Sponsor: Bacoba AG | Active, not recruiting ➔ Completed

Trial completion

Safety, Tolerability, and Pharmacokinetics of BAP5191 in Healthy Adults Following Topical Application of Repeat Doses (clinicaltrials.gov) - P1 | N=24 | Active, not recruiting | Sponsor: Bacoba AG | Recruiting ➔ Active, not recruiting | Trial completion date: Sep 2023 ➔ Mar 2024 | Trial primary completion date: Jul 2023 ➔ Mar 2024

Enrollment closed • Trial completion date • Trial primary completion date

Safety, Tolerability, and Pharmacokinetics of BAP5191 in Healthy Adults Following Topical Application of Repeat Doses (clinicaltrials.gov) - P1 | N=24 | Recruiting | Sponsor: Bacoba AG

New P1 trial